Identification of "toxicophoric" features for predicting drug-induced QT interval prolongation

被引:11
作者
Coi, Alessio [1 ]
Massarelli, Ilaria [2 ]
Testai, Lara [3 ]
Calderone, Vincenzo [3 ]
Bianucci, Anna Maria [1 ]
机构
[1] Univ Pisa, Dipartimento Sci Farmaceut, I-56126 Pisa, Italy
[2] Univ Pisa, Dipartimento Chim & Chim Ind, I-56126 Pisa, Italy
[3] Univ Pisa, Dipartimento Psichiatria Neurobiol Farmacol & Bio, I-56126 Pisa, Italy
关键词
hERG K+ channel; Toxicophore; QT interval prolongation; Molecular modeling; Homology building;
D O I
10.1016/j.ejmech.2007.12.025
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Drugs delaying cardiac repolarization by blockade of hERG K+ channel generally prolong the QT interval of the electrocardiogram, an effect regarded as a cardiac risk factor with the potential to cause 'torsade des pointes'-type arrhythmias in humans. The present study applied a homology building technique and molecular dynamics simulations to model the pore of hERG K+ channel. A docking analysis was then performed on selected ligands which were classified as QT-prolonging or non-prolonging after experimental measurements in in vivo anesthetized guinea pig. The results of this structural analysis provided a "toxicophoric" model that was further exploited to inspect a dataset of known QT-prolonging/non-prolonging molecules. The emerging major chemical features to be avoided, in order to obtain cardiac safe therapeutic agents, comprise the simultaneous presence of (i) a protonated nitrogen atom within an observed range of distances from a heteroatom; (ii) aromatic groups capable of interacting within an area defined by Gly657 residues of the pore or within an area located at the top of the longitudinal axis of the pore. Moreover, additional hydrophobic moieties interacting with one of the equatorial cavities located in the area near-by Tyr652 residues and/or with a hydrophobic fing defined by Phe656 residues should be avoided. (C) 2007 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:2479 / 2488
页数:10
相关论文
共 50 条
[1]   A model for identifying HERG K+ channel blockers [J].
Aronov, AM ;
Goldman, BB .
BIOORGANIC & MEDICINAL CHEMISTRY, 2004, 12 (09) :2307-2315
[2]   Predictive in silico modeling for hERG channelblockers [J].
Aronov, MM .
DRUG DISCOVERY TODAY, 2005, 10 (02) :149-155
[3]   Toward a pharmacophore for drugs inducing the long QT syndrome:: Insights from a CoMFA study of HERG K+ channel blockers [J].
Cavalli, A ;
Poluzzi, E ;
De Ponti, F ;
Recanatini, M .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :3844-3853
[4]  
Cavero I, 2000, Expert Opin Pharmacother, V1, P947, DOI 10.1517/14656566.1.5.947
[5]  
Cheng Hsien C., 2006, Journal of Pharmacological and Toxicological Methods, V54, P278, DOI 10.1016/j.vascn.2006.01.002
[6]   Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels [J].
Chiu, PJS ;
Marcoe, KF ;
Bounds, SE ;
Lin, CH ;
Feng, JJ ;
Lin, A ;
Cheng, FC ;
Crumb, WJ ;
Mitchell, R .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 95 (03) :311-319
[7]   A novel hypothesis for the binding mode of HERG channel blockers [J].
Choe, H ;
Nah, KH ;
Lee, SN ;
Lee, HS ;
Lee, HS ;
Jo, SH ;
Leem, CH ;
Jang, YJ .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 344 (01) :72-78
[8]   Comparison of the effects of metoclopramide and domperidone on HERG channels [J].
Claassen, S ;
Zünkler, BJ .
PHARMACOLOGY, 2005, 74 (01) :31-36
[9]   Prediction of hERG potassium channel affinity by the CODESSA approach [J].
Coi, A ;
Massarelli, I ;
Murgia, L ;
Saraceno, M ;
Calderone, V ;
Bianucci, AM .
BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (09) :3153-3159
[10]  
*CPMP, 1997, CPMP98696